AU2006234897A1 - Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures - Google Patents

Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures Download PDF

Info

Publication number
AU2006234897A1
AU2006234897A1 AU2006234897A AU2006234897A AU2006234897A1 AU 2006234897 A1 AU2006234897 A1 AU 2006234897A1 AU 2006234897 A AU2006234897 A AU 2006234897A AU 2006234897 A AU2006234897 A AU 2006234897A AU 2006234897 A1 AU2006234897 A1 AU 2006234897A1
Authority
AU
Australia
Prior art keywords
affymetrix
gene
expression
seq
probe set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006234897A
Other languages
English (en)
Inventor
Gennadi V. Glinksii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sidney Kimmel Cancer Center
Original Assignee
Sidney Kimmel Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidney Kimmel Cancer Center filed Critical Sidney Kimmel Cancer Center
Publication of AU2006234897A1 publication Critical patent/AU2006234897A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2006234897A 2005-03-16 2006-03-16 Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures Abandoned AU2006234897A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66301405P 2005-03-16 2005-03-16
US60/663,014 2005-03-16
PCT/US2006/009870 WO2006110264A2 (en) 2005-03-16 2006-03-16 Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures

Publications (1)

Publication Number Publication Date
AU2006234897A1 true AU2006234897A1 (en) 2006-10-19

Family

ID=37087482

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006234897A Abandoned AU2006234897A1 (en) 2005-03-16 2006-03-16 Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures

Country Status (5)

Country Link
US (1) US8349555B2 (cg-RX-API-DMAC10.html)
EP (1) EP1874471A4 (cg-RX-API-DMAC10.html)
JP (2) JP2008536488A (cg-RX-API-DMAC10.html)
AU (1) AU2006234897A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006110264A2 (cg-RX-API-DMAC10.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130122504A1 (en) * 2011-11-14 2013-05-16 Lars Dyrskjot Andersen Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer
WO2007013480A2 (en) * 2005-07-29 2007-02-01 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
DE102007044919A1 (de) * 2007-09-19 2009-04-02 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Verfahren zur Bestimmung von sekundärem Therapieversagen
JP5407018B2 (ja) * 2007-12-28 2014-02-05 国立大学法人名古屋大学 肺腺癌患者の術後再発を予測するための方法及び組成物
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
JP5461959B2 (ja) * 2008-10-31 2014-04-02 株式会社Ｄｎａチップ研究所 神経膠腫予後予測方法、およびそれに用いるキット
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
EP2433232A1 (en) * 2009-05-20 2012-03-28 Koninklijke Philips Electronics N.V. Biomarkers based on sets of molecular signatures
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CA3081061C (en) * 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US20140377220A1 (en) * 2011-11-23 2014-12-25 Uti Limited Partnership Gene expression signatures for staging and prognosis of prostate, breast and leukemia cancers
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
MX351626B (es) 2012-01-31 2017-10-23 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
CA2884737A1 (en) * 2012-08-16 2014-02-20 The Trustees Of Columbia University In The City Of New York Diagnostic markers of indolent prostate cancer
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
KR101993716B1 (ko) * 2012-09-28 2019-06-27 삼성전자주식회사 카테고리별 진단 모델을 이용한 병변 진단 장치 및 방법
US9687290B2 (en) 2012-10-02 2017-06-27 Covidien Lp Energy-based medical devices
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
EP2971137B1 (en) * 2013-03-15 2018-05-09 The Broad Institute, Inc. Methods for the detection of dna-rna proximity in vivo
EP3014505A4 (en) * 2013-06-28 2017-03-08 Nantomics, LLC Pathway analysis for identification of diagnostic tests
ES2738289T3 (es) 2013-11-06 2020-01-21 Hospital Clinic Barcelona Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
FR3017955B1 (fr) * 2014-02-27 2018-04-06 Assistance Publique - Hopitaux De Paris Biomarqueurs diagnostics de la cardiomyopathie du peripartum
WO2016036878A1 (en) * 2014-09-02 2016-03-10 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
TWI582240B (zh) * 2015-05-19 2017-05-11 鄭鴻鈞 以基因體預後評估試劑組預測乳癌患者局部區域復發風險及放射治療有效性的方法、用途及裝置
JP6991134B2 (ja) * 2015-10-09 2022-01-12 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａを使用する集団ベースの処置レコメンダ
ES2859423T3 (es) 2016-04-20 2021-10-04 Us Health Evaluación del linfoma de células del manto y procedimientos relacionados con el mismo
US20180057890A1 (en) 2016-05-19 2018-03-01 Llew Keltner Methods of diagnosis and therapeutic targeting of clinically intractable malignant tumors
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
AU2018230784A1 (en) 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
EP3715476A1 (en) 2019-03-29 2020-09-30 Centre National De La Recherche Scientifique Prognosis method of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
PT1410011E (pt) * 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnóstico e prognóstico de pacientes com cancro da mama
AU2002358279A1 (en) 2001-12-21 2003-07-30 Arcturus Engineering, Inc. Biomarkers for breast cancer
EP1552293A4 (en) * 2002-09-10 2006-12-06 Guennadi V Glinskii METHOD FOR SEGREGATION OF GENES AND CLASSIFICATION OF BIOLOGICAL SAMPLES
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
US8065093B2 (en) * 2004-10-06 2011-11-22 Agency For Science, Technology, And Research Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers
US20060160169A1 (en) * 2004-12-03 2006-07-20 Board Of Regents, The University Of Texas System Cell microarray for profiling of cellular phenotypes and gene function
US7890267B2 (en) * 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
US20090098538A1 (en) * 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy

Also Published As

Publication number Publication date
JP2009131278A (ja) 2009-06-18
EP1874471A4 (en) 2008-12-10
JP2008536488A (ja) 2008-09-11
WO2006110264A2 (en) 2006-10-19
US8349555B2 (en) 2013-01-08
US20090233279A1 (en) 2009-09-17
WO2006110264A3 (en) 2007-03-01
EP1874471A2 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
US8349555B2 (en) Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
US8781750B2 (en) Cell-type-specific patterns of gene expression
JP4938672B2 (ja) ｐ５３の状態と遺伝子発現プロファイルとの関連性に基づき、癌を分類し、予後を予測し、そして診断する方法、システム、およびアレイ
EP2114990B1 (en) Method for predicting the response of NSCLC-patients to treatment by an EGFR-TK inhibitor
EP2253721A1 (en) Method for predicting the occurence of lung metastasis in breast cancer patients
WO2008031041A2 (en) Melanoma gene signature
KR20140105836A (ko) 다유전자 바이오마커의 확인
US20090192045A1 (en) Molecular staging of stage ii and iii colon cancer and prognosis
EP2081950A2 (en) Expression profiles associated with irinotecan treatment
AU2008203226B2 (en) Colorectal cancer prognostics
CN103998064A (zh) 治疗后的乳腺癌预后
US9195796B2 (en) Malignancy-risk signature from histologically normal breast tissue
EP1668151B1 (en) Materials and methods relating to breast cancer diagnosis
TW201827603A (zh) 用於膀胱癌預後的生物標記物組合
CA2767246A1 (en) Tivozanib response prediction
WO2007041238A2 (en) Methods of identification and use of gene signatures
JP5963748B2 (ja) 中枢神経原発悪性リンパ腫患者の予後予測方法、キット及び使用
WO2018187673A1 (en) Mirna signature expression in cancer
EP2872651A1 (en) Gene expression profiling using 5 genes to predict prognosis in breast cancer
JP2011211989A (ja) 悪性神経膠腫患者の予後予測方法

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period